VasoRx raised $31.89 million to advance its RNA therapy platform for the treatment of pulmonary hypertension, a rare cardiovascular disease.
VasoRx raised $31.89 million to advance its RNA therapy platform for the treatment of pulmonary hypertension, a rare cardiovascular disease.